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2ABSTRACT1
The biodistribution of transgene expression in the CNS after localized stereotaxic vector 2
delivery is an important issue for safety of gene therapy for neurological diseases. The 3
cellular specificity of transgene expression from rAAV2/1 vectors using the tetON expression 4
cassette in comparison with the CMV promoter was investigated in the rat nigrostriatal 5
pathway.  After intrastriatal injection, although GFP was mainly expressed into neurons with 6
both vectors, the percentage of GFP+ astrocytes was 5-fold higher with the CMV vector. The 7
relative proportions of DARPP-32+ projection neurons and parvalbumin+ interneurons were 8
respectively 13:1 and 2:1 for the CMV and tetON vectors. DARP32+ neurons projecting to the 9
globus pallidus were strongly GFP+ with both vectors, whereas those projecting to the 10
substantia nigra pars reticulata (SNpr) were efficiently labeled by the CMV but poorly by the 11
tetON vector. Numerous GFP+ cells were evidenced in the subventricular zone with both 12
vectors. However, in the olfactory bulb (OB), GFP+ neurons were observed with the CMV but 13
not the tetON vector. We conclude that the absence of significant amounts of transgene 14
product in distant regions (SN and OB) constitutes a safety advantage of the AAV2/1-tetON 15
vector for striatal gene therapy.16
Midbrain injections resulted in selective GFP expression in tyrosine hydroxylase+ neurons by 17
the tetON vector whereas with the CMV vector, GFP+ cells covered a widespread area of the 18
midbrain. The biodistribution of GFP protein corresponded to that of the transcripts and not of 19
the viral genomes. We conclude that the rAAV2/1-tetON vector constitutes an interesting tool 20
for specific transgene expression in midbrain dopaminergic neurons.21
22
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3 INTRODUCTION1
An AAV serotype 2 vector constitutively expressing Neurturin, a glial cell line-2
derived neurotrophic factor (GDNF) analog has shown promising results in a phase I clinical 3
trial (Marks et al., 2008).  However, adverse effects which have been described after 4
administration of GDNF recombinant protein delivery (Nutt et al., 2003; Hovland et al., 5
2007) or uncontrolled GDNF gene transfer (Kirik et al., 2000a; Georgievska et al., 2002; 6
Eslamboli et al., 2005) should be taken into account for future developments. These clinical 7
trials and animal studies have shown that key factors for the success of this therapeutical 8
approach are: a widespread  distribution of GDNF in the putamen (Kirik et al., 2000b;9
Peterson and Nutt , 2008) ; the absence of significant GDNF tissue concentrations in the 10
substantia nigra which has been shown  to induce aberrant sprouting (Georgievska et al., 11
2002) as well as an optimal dose of GDNF providing neuroprotection in the absence of 12
metabolic effects (Eslamboli et al., 2005). Therefore, an ideal viral vector for GDNF gene 13
delivery in Parkinson’s disease should: -diffuse to a significant portion of the striatum; -not 14
transduce projecting neurons, in particular the gaba-ergic neurons projecting to the substantia 15
nigra pars reticulata; -not be retrogradely transported, in particular to the substantia nigra pars 16
compacta;  -allow to modulate and eventually switch-off transgene expression.17
Different AAV serotypes show different cellular tropisms in the brain (Davidson et al., 18
2000; Passini et al., 2003; Burger et al., 2004; Paterna et al., 2004; McCown, 2005; Cearley 19
et al., 2006; Taymans et al., 2007; Klein et al., 2008). Cross-packaging of vectors using ITRs 20
from AAV2 with capsids from other serotypes (Rabinowitz et al., 2002) allowed to evaluate 21
the contribution of the capsid to the cellular transduction specificity in the brain (Wang et al., 22
2003; Burger et al., 2004; Paterna et al., 2004; Cearley et al., 2006; Klein et al., 2006; Klein 23
et al., 2008). It has been suggested that receptors differentially expressed on the cell surface 24
account for the observed differences. Indeed, AAV2 utilizes heparan sulfate proteoglycans as 25
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4receptor (Summerford and Samulski, 1998) and FGF-R (Qing et al., 1999) and V5-integrin 1
(Summerford et al., 1999) as co-receptors, AAV5 utilizes PDGF receptor (Di Pasquale et al., 2
2003) and sialic acid (Walters et al., 2001) for internalization whereas AAV1 and AAV6 3
require alpha2,3 and alpha2,6 N-linked sialic acids for efficient binding (Wu et al., 2006). As 4
a consequence of these different mechanisms of cell entry, the biodistribution of trangene 5
expression in the brain depends on the serotype. In particular, AAV2-mediated transduction 6
of the striatum is restricted to the vicinity of the delivery site, whereas a widespread 7
distribution of the transgene product can be obtained with a single injection of AAV1, AAV5, 8
AAV7 or AAV8 (Taymans et al., 2007).9
However, the promoter used to drive transgene expression also influences the cellular 10
specificity as well as the time course of transgene expression. Klein and coll. (Klein et al., 11
1998) have first demonstrated that the decrease of transgene expression initially observed 12
with AAV2 vectors using the CMV promoter can be overcome by using the cellular neuron-13
specific enolase (NSE) promoter. Furthermore, discrepancies observed between the cellular 14
specificity of transgene expression from rAAV vectors of a defined serotype, suggest that 15
capsid entry is not the only factor involved. For example, in the mouse striatum, transgene 16
was expressed in both neurons and astrocytes when using rAAV2/1-CMV (Wang et al., 2003)17
whereas transgene expression was restricted to neurons when using rAAV2/1 with the GUSB 18
promoter (Paterna et al., 2004). A direct demonstration that promoter usage affects the 19
cellular specificity of transgene expression came from a study of Haberman and coll. 20
(Haberman et al., 2002) showing that rAAV2/2 vectors using respectively the CMV promoter 21
and the tetOFF system were driving transgene expression in distinct subpopulations of 22
neurons resulting in opposite physiological effects.23
The tet promoter consists in a minimal CMV promoter in which the enhancer sites 24
have been replaced by tetracycline operator sites (Gossen and Bujard, 1992). These operator 25
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5sites bind the tTA/rtTA transactivator (Gossen and Bujard, 1992; Gossen et al., 1995), a 1
synthetic transcription factor in which the transactivating domain derives from the Herpes 2
VP16 transactivator and the DNA-binding domain from the bacterial tetracycline repressor.3
Both humoral and cytotoxic immune responses directed against the tTA/rtTA transactivator 4
and severely impairing transduction efficiency have been reported after intramuscular (Favre 5
et al., 2002) but not intracerebral administration (Fitzsimons et al., 2001; Xiong et al., 2008).6
Direct gene transfer into the brain also has potential for studying gene function. 7
However, because of the heterogenous cellular composition of the brain, cell type-specific 8
gene expression would constitute a valuable tool for studying functional genomics as well as 9
for better controlled gene therapy applications.10
11
12
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6MATERIAL AND METHODS1
2
Plasmids3
The pAC1-M2-WPRE plasmid comprising AAV ITRs bracketing the bidirectional 4
tetracycline-responsive cassette expressing both rtTAM2 and EGFP and the Woodchuck 5
hepatitis virus posttranscriptional regulatory element (WPRE) (Donello et al., 1998)6
introduced immediately downstream to the rtTAM2 sequence has been described previously7
(Chtarto et al.,2007). 8
9
Recombinant viruses10
High titers of recombinant rAAV2/1-rtTAM2- EGFP, rAAV2/1-rtTAM2-WPRE-EGFP and 11
recombinant rAAV2/1-CMV-EGFP viral stocks were produced at the Gene Vector 12
Production Network (Laboratoire de Thérapie Génique, Nantes, France) as described (Salvetti 13
et al.,1999). Titers expressed as viral genomes per ml were: rAAV2/1-rtTAM2-WPRE-EGFP, 14
1.7 X 1011; rAAV2/1-rtTAM2-EGFP, 2 X 1011, rAAV2/1-CMV-EGFP, 2.0 X 1011, rAAV1-15
rtTAM2-GDNF, 7.0 X 1011.16
17
Stereotaxic injections18
Adult female Wistar rats of 250g (Harlan, Indianapolis, Indiana) were used for unilateral19
intracerebral injections as previously described (Tenenbaum et al., 2000). The animals were 20
anesthetized using a mixture of ketamine (Ketalar, Pfizer, New York City, NY; 100 mg kg-1 21
ip) and xylazin (Rompun, Bayer, Leverkusen, Germany; 10mg kg-1 ip). Injections were made 22
according to coordinates defined by Paxinos and Watson (Paxinos and Watson, 1997) using a 23
Kopf stereotaxic apparatus (David Kopf, Tujunga, California). The injection coordinates were 24
respectively for the striatum, 0.5 mm anterior, 2.8 mm lateral to bregma and 5 mm below the 25
dural surface and 5.3 mm posterior, 2.2 mm lateral to bregma and 6.6 mm below the dural 26
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7surface for the midbrain. Viral particles diluted in 2 µl D-PBS (BioWittaker, Walkersville, 1
MD) were infused using a motor-driven Hamilton syringe (Bonaduz, Switserland; 0.2 µl/ 2
min.) with a 30G needle. After injection, the needle was left in place for 5 minutes in order to 3
allow diffusion of the viral suspension in the parenchyma. The needle was then slowly lifted 1 4
mm up and left in place 5 minutes, then slowly removed. Since after the surgery, the animals 5
were given water containing 3% sucrose and doxycycline (600 µg/ml or 1g/l for qPCR 6
analysis). 7
Animals were killed at the indicated time after surgery by an overdose of anesthetic (200 mg  8
kg-1 ketamine and 20 mg kg-1 xylazine). For immunohistological analysis, animals were 9
perfused through the ascending aorta first with 150-200 ml of saline (NaCl 0.9%), then with 10
300 ml 4% paraformaldehyde in  0.1M phosphate buffer (PF4). After overnight post-fixation 11
in PF4 at 4°C, brains were transferred to phosphate buffer saline (PBS) and stored at 4°C. 12
13
GDNF ELISA assay14
For determination of GDNF brain tissue levels, animals were decapitated and the brains were 15
removed, gradually frozen in isopentane/dry ice (-10°C for 10 sec. then -20°C for 20 sec.) and 16
stored at –80°C. Two hundred micron coronal slices were cut using a cryostat and striata and 17
midbrains were dissected out, weighed and processed for ELISA assay.  Tissue was sonicated 18
(Branson Sonifier 250, output 2, 30% duty cycle, 10 sec(Branson Ultrasonics, Danbury, CT) 19
in M-Per buffer (Pierce, Thermo Fisher Scientific Inc., Rockford, IL) supplemented with 20
protease inhibitors cocktail (Boehringer Ingelheim GmbH, Ingelheim, Germany). Samples 21
were centrifuged at 10,000 x g and supernatants were harvested and their protein 22
concentration analysed using the BCA Assay kit (Pierce, Thermo Fisher Scientific Inc., 23
Rockford, IL). GDNF tissue levels were measured according to the manufacturer’s protocol 24
(BioSource, Nivelles, Belgium) and expressed in pg per mg of tissue. Recombinant human 25
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8GDNF (R&D System, Minneapolis, MN) was used to establish the standard curve. A cross 1
reaction of 100% was demonstrated with recombinant rat GDNF (Oncogene Research 2
Products, Calbiochem, Merck, Frankfurter, Germany).3
4
Immunofluorescence5
Coronal sections (50 µm) obtained using a vibratome (Leica Microsystems, Wetzlar, 6
Germany) were sequentially incubated in: i) THST (50mM Tris, 0.5 M NaCl, 0.5% Triton 7
X100 (Merck, Frankfurter, Germany) pH7.6) containing 10% horse serum for 2 hours.; ii)8
rabbit anti-GFP IgG (1:3000, Molecular Probes, Invitrogen, Carlsbad, CA) diluted in THST 9
containing 5% horse serum for 16 hours at 4°C; iii) donkey anti rabbit IgG conjugated with 10
biotin (Amersham, GE Healthcare, Munich, Germany) diluted 1:600 in THST  containing 5% 11
horse serum, 2 hour at room temperature; iv) streptavidin conjugated to cyanine 2 (1:300; 12
Jackson ImmunoResearch, West Grove, PA) in THST containing 5% horse serum, 2 hours at 13
room temperature. Three washings in TBS (Tris 10mM, NaCl 0.9%, pH7.6) of 10 min. were 14
performed between each step. 15
For double immunofluorescence, these incubations were combined with mouse monoclonal 16
antibodies (anti-NeuN (1:200, Chemicon, Millipore, Billerica, MA); anti-glutamic acid 17
decarboxylase (1:200, Chemicon, Millipore, Billerica, MA); anti-parvalbumin (1:2000, 18
Sigma-Aldrich, St Louis, MO) or anti-glial fibrillary acid protein (GFAP, 1:200, Chemicon, 19
Millipore, Billerica, MA)) (step ii); and donkey anti-mouse IgG coupled to cyanine 3 (1:200; 20
Jackson ImmunoResearch, West Grove PA) in THST containing 5% horse serum)  (step iv).21
For DARPP-32/GFP immunofluorescence, a mouse monoclonal anti-gfp antibody (a gift from 22
J.D.Franssen, Euroscreen, Gosselies, Belgium) at a 1:50 dilution was combined with rabbit23
anti DARPP-32 IgG (1:200, Chemicon, Millipore, Billerica, MA) in THST containing 5% 24
horse serum 16 hours at 4°C (step ii). The primary antibodies were detected using a donkey 25
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9anti-rabbit IgG conjugated with biotin (1:200, Amersham, GE Healthcare, Munich, Germany) 1
and a goat anti-mouse IgG conjugated with horseradish peroxidase (HRP) antibody (1:100, 2
from tyramide signal amplification (TSA) kit, Molecular Probes, Invitrogen, Carlsbad, CA) 3
diluted in Blocking Reagent provided by the TSA kit (Molecular Probes, Invitrogen, 4
Carlsbad, CA), 1 hour at room temperature (step iii). Step iv was performed as described 5
above. Step v: the monoclonal anti-gfp then revealed using the TSA kit according to 6
manufacturer’s protocol.7
Sections were mounted using FluorSave mounting fluid for fluorescence (Calbiochem, 8
Merck, Frankfurter, Germany) and photographed using a Zeiss Axiophot 2 microscope 9
equipped with FITC and TRITC filters (Car Zeiss, Göttingen, Germany) as well as an 10
AxioCam digital camera (Carl Zeiss, Gottingen, Germany). Images were acquired as jpeg 11
files using the KS300 software (Car Zeiss, Gottingen, Germany).12
13
Confocal microscopy14
Co-labelling analysis were performed on pictures taken on at least three different sections 15
within the transduction zone using an automatic image analysis system (Lasersharp version 16
3.2 (Biorad, Hercules, CA) coupled to Axiovert 100  microscope, (Carl Zeiss, Gottingen, 17
Germany)).  Pictures were then processed and analysed with the Image J software (NIH, 18
USA)19
20
Stereology21
The number of GFP-positive cells and the volume of the labelled brain area were evaluated by 22
stereological procedures based on the Cavalieri principle (Sterio, 1984). For each animal, 23
serial sections with an interval of 500 µm were analyzed by means of  the optical fractionator 24
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10
of the Stereoinvestigator software (MBF Bioscience, Williston, VT) connected with a CCD1
video camera to the microscope (Leica Microsystems, Wetzlar, Germany).2
3
Immunohistochemistry4
For GFP stainings, cryostat sections (50 µm) were sequentially incubated in: i) 3% H2O2 in 5
TBS (Tris 10mM, 0.9% NaCl, pH7.6) for 30 min.; ii) THST (50mM Tris, 0.5 M NaCl, 0.5% 6
Triton X100 pH7.6) containing 10% horse serum for 1 hour.; iii) rabbit anti-GFP IgG7
(Clonetech, Palo Alto, CA) diluted 1:3000 in THST containing 5% horse serum overnight at8
4°C; iv) donkey anti rabbit IgG conjugated with biotin (Amersham, GE Healthcare, Munich, 9
Germany) 1:600 in THST containing 5% horse serum, 2 hours at room temperature. The 10
peroxidase staining was revealed using the ABC Elite vectastain kit and diaminobenzidine 11
(Vector, NTL Laboratories, Brussels, Belgium), according to the manufacturer’s protocol. 12
Sections were mounted on gelatin-coated slides, dehydrated and mounted using DPX 13
mounting fluid (Sigma-Aldrich, St Louis, MO). Sections were photographed using a Zeiss 14
Axiophot 2 microscope (Carl Zeiss, Gottingen, Germany). 15
For CD5 and CD11b stainings, an identical protocol was used for steps i) and ii), then 16
sections were incubated with mouse anti-CD5 IgG (1:500, Serotec, MorphoSys, Dusseldorf, 17
Germany) or mouse anti-CD11b IgG (1:500, Serotec, MorphoSys, Dusseldorf, Germany) 18
(step iii),  then goat anti-mouse IgG conjugated with HRP (Molecular Probes, Invitrogen, 19
Carlsbad, CA, from TSA kit) diluted in Blocking Reagent provided with the TSA kit 20
(Molecular Probes, Invitrogen, Carlsbad, CA) was added for 2 hours at room temperature21
(step iv); and v) diaminobenzidine (Vector, NTL Laboratories, Brussels, Belgium), according 22
to the manufacturer’s protocol. Sections were photographed using a Zeiss Axiophot 2(Carl 23
Zeiss, Gottingen, Germany) microscope and optical density of defined regions at short 24
distance from the needle tract (10 µm) measured using the Image J Software (NIH, USA).25
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11
The ratio of the mean optical densities of 3 sections on the injected side and symmetrical 1
sections on the intact side was taken as a measure of microglial cells activation (CD11b) or T 2
cells infiltration (CD5) induced by vector injection and transgene expression.3
4
Tissue sample collection5
Animals injected with 4.0 X 108 viral particles of rAAV2/1-rtTAM2-EGFP or rAAV2/1-6
CMV-EGFP were anesthetized using an overdose of anesthetic (200 mg kg-1 ketamine and 20 7
mg kg-1 xylazine i.p.) and then decapitated. The brains were dissected out and frozen to -20°C 8
in a bath of methyl-butane using dry ice, before transfer to -80°C for conservation. The brains 9
were equilibrated 1 hour at -20°C before being sliced into 1 mm thick sections using a brain 10
matrix (Alto, Roboz, Gaithersburg, MD). Tissue punches corresponding to the substantia 11
nigra or to the dorsal midbrain were collected from 3 slices around the injection site. Samples 12
were then kept at -80°C before RNA and Hirt DNA extraction.13
14
mRNA extraction15
Messenger RNA extractions were performed using the MagNA Pure LC Instrument (Roche 16
Applied Bioscience, Basel, Switserland) using the MagNA Pure LC mRNA Isolation kit II 17
(Roche Applied , Basel, Switserland) according to the manufacturer’s recommendations.18
19
Hirt low molecular weight DNA extraction20
Tissue samples (approx. 10 mg) were homogenized in 300 µl lysis buffer (Tris 10 mM pH 21
8.0, EDTA 10 mM, SDS 1%) containing 1 µl of DNase-free RNase (10 mg/ml; Roche 22
Applied Bioscience, Basel, Switserland) and Proteinase K (Roche Applied Bioscience, Basel, 23
Switserland) were added to final concentrations of 0.5 and 1 mg/ml, respectively. The 24
reaction was continued for 120 min at 37°C, after which NaCl was added to a final 25
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12
concentration of 1.1 M. Following overnight precipitation at 4°C, samples were centrifuged at 1
14,000 rpm in a tabletop microcentrifuge for 1 hour and low molecular weight DNA (hDNA) 2
(Hirt, 1967) was purified from the supernatant by standard phenol-chloroform extractions 3
(twice), chloroform extractions (twice) and ethanol precipitation. The final DNA pellet was 4
resuspended in 50 µl of TE buffer. Fuether RNase digestion was performed for 30 min at 5
room temperature by adding RNase (DNase free, Roche Applied Bioscience, Basel, 6
Switserland) at a final concentration of 0.2 ng/ µl).7
8
Reverse transcription9
mRNA samples were converted to cDNA using the Transcriptor First Strand cDNA Synthesis 10
Kit (Roche Applied Bioscience, Basel, Switserland) according to the manufacturer’s 11
recommendations using 3 µl of the RNA sample and anchored-oligo (dT)18 primers.12
13
Real-time quantitative PCR14
Gfp sequences were quantified using real time SYBRgreen quantitative PCR analysis (Roche 15
Applied Bioscience, Basel, Switserland) on a LightCycler 1.5 apparatus (Roche Applied 16
Bioscience, Basel, Switserland). Tyrosine 3-monooxygenase/tryptophan 5 monooxygenase 17
activation protein, zeta polypeptide (YWHAZ) and actin 2 house keeping genes were used to 18
normalize gfp expression levels. Primers used were: for gfp: forward: 5’-19
GCAGAAGAACGGCATCAAGGT-3’; reverse: 5’-ACGAACTCCAGCAGGACCATG-3’, 20
for actin 2: forward: 5’-TACCCTATTGAGCACGGCAT-3’; reverse: 5’-21
CGCAGCTCGTTGTAGAAGGT-3’ and for YWHAZ: forward: 5’-22
CAAGCATACCAAGAAGCATTTGA-3’; reverse: 5’-GGGCCAGACCCAGTCTGA-3’. 23
PCR conditions were: 95°C for 10 min, 45 cycles of 95°C 10 sec, 60°C 30 sec, 72°C 20 sec 24
using 5 µl of the sample. Hirt DNA samples were analyzed for gfp copy number using a 25
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13
standard curve based on serial dilutions of plasmids containing a rAAV genome harbouring 1
the gfp sequence. cDNA samples were analyzed expression levels of gfp, actin 2 and 2
YWHAZ. Data analysis and normalizations were performed using the qBase software (Ghent 3
University, Belgium).4
5
Statistical analyses6
For all data, exept qPCR results, the means ± standard deviations are shown. For qPCR data, 7
the mean ± standard error of the mean are given.8
Data were analyzed using the Graph Pad Software Prism 3.0 (Graph Pad Software, La Jolla, 9
CA). Unpaired Student t tests or one-way ANOVA were performed as indicated.10
11
Animal housing and ethics12
Animals were maintained, 4 in each cage, in a 12:12 h light–dark cycle with free access to rat 13
chow and water. All experimental procedures were conducted in accordance with the Belgium 14
Biosafety Advisory Committee and with the ethical committee of the Faculty of Medicine 15
(CEBEA, ULB).16
17
18
19
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RESULTS1
2
1. Intrastriatal injection3
4
1.1.Striatum5
We have previously shown that the rAAV2/1-tetON vector drives doxycycline (dox)-6
dependent GDNF expression in the rat striatum (Chtarto et al., 2007). We have extended 7
these data and shown that the striatal amount of GDNF could be modulated in function of the 8
dox dose (Fig. 1).9
Since GDNF is secreted, it does not allow an immuno-histological identification of 10
transduced cells. Therefore, in the present study, we have used vectors expressing GFP, which 11
have an intracellular localisation.12
Four 108 viral particles of crosspackaged rAAV2/1-rtTA-M2-WPRE-EGFP and rAAV2/1-13
CMV-EGFP were infused into the right striatum of adult rats.14
GFP-positive cells were observed in a widespread region of the forebrain (Fig.. 2 a,b)15
covering a volume of 32.06 ± 10.84 mm3 and 28.48 ± 3.49 mm3 for the CMV and tetON 16
vectors, respectively. GFP-positive cells were mainly located in the striatum but also in the 17
globus pallidus, the sub-ventricular zone and the external capsule. The total number of GFP-18
positive cells per animal was significantly higher (p< 0.001; Student t test) for the CMV 19
vector (103,131 ± 8,469; n=4) than for the tetON vector (46,298 ± 5,545; n=4).20
The majority of GFP-positive cells colabeled with the NeuN neuronal marker (85.1±4.7% and 21
89.2 ±6.1% for the CMV and the tetON vector, respectively; Fig.3). However, the relative 22
proportion of DARPP-32 gaba-ergic neurons and parvalbumin-positive interneurons varied 23
between the 2 vectors. Significantly more DARPP-32-positive cells were expressing GFP 24
with the CMV vector (91.6±2.3% of the GFP-positive cells versus 66.7±5.1 % for the tetON 25
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vector; p< 0.001, Student t test; Fig. 3b) whereas significantly more parvalbumin-reactive 1
neurons were expressing GFP with the tetON vector (29.0±10.9% versus 7.1±1.3% for the 2
CMV vector; p< 0.05, Student t test; Fig.3b). 3
The CMV vector lead to GFP expression in relatively more astrocytes (5.9 ± 1.9 % of GFP-4
positive cells) than the tetON vector (1.2 ± 2.2%) (p < 0.05; Fig.3b).5
6
1.2.Anterograde transport to the globus pallidus and substantia nigra pars reticulata7
GFP-positive fibers were observed in the substantia nigra pars reticulata (SNr) after 8
intrastriatal injection  of the CMV (Fig. 4a) but not of the tetON vector (data not shown). 9
These GFP-positive fibers were co-labeled using an antibody directed toward glutamic acid 10
decarboxylase (GAD) (Fig. 4a) characterizing the efferent projections of striatal gaba-ergic 11
inhibitory neurons. These data suggest that striato-nigral gaba-ergic projection neurons were 12
efficiently expressing GFP when using the CMV but not the tetON vector. It should be noted 13
that using a sensitive peroxidase biotin/streptavidin amplified immunohistochemistry for 14
GFP, stained fibers could be evidenced in the SNr of rAAV2/1-tetON-injected animals (Fig. 15
4b). The staining was however weaker than for the CMV vector (Fig. 4b). To compare the 16
intensity of the stainings, the ratio of the mean optical densities of 3 sections on the injected 17
versus intact sides was taken as a measure of fiber density and was found to be significantly 18
lower for the tetON vector (Fig. 4c). The extent of the staining was also more restricted for 19
the tetON vector. Indeed, it covered a smaller part of the SNr (Fig.4b). The antero-posterior 20
distribution of the labeled region was similar for both vectors (data not shown). 21
Accordingly, intrastriatal injection of AAV2/1 vectors expressing the GDNF cDNA, resulted 22
in low amounts of GDNF (not significantly higher than the endogenous level) in the 23
substantia nigra (Fig.1). 24
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In contrast, GFP-positive projections of DARPP-32-positive gaba-ergic neurons in the globus 1
pallidus were evidenced with both the CMV and the tetON vector (Fig. 4b) and the fiber 2
densities were not significantly different for the 2 vectors (Fig. 4c). 3
4
1.3.Retrograde transport to substantia nigra pars compacta5
After intrastriatal injection of rAAV2/1-CMV-EGFP,  GFP-positive cells (111.7±30.7 per 6
animal; n=3) co-labeling with the dopaminergic neuron marker tyrosine hydroxylase were 7
evidenced in the SNpc (Fig. 5), suggesting that rAAV2/1 viral particles were retrogradely 8
transported from the injection site in the striatum to the SNpc. In contrast, no GFP-positive 9
cell was detected by immunofluorescent labeling in the tetON vector group (data not shown). 10
To determine if a weak GFP expression from the tetON vector could be evidenced using a 11
more sensitive detection technique, midbrain sections were labeled by immunohistochemistry 12
for GFP using a sensitive biotin-streptavidin amplification step (see Material and Methods). 13
Few weakly labeled GFP-positive cells were evidenced in the SNpc of AAV-tetON injected 14
animals (data not shown).15
16
1.4. Subventricular zone17
It has been previously reported that, injection of rAAV2/1 vectors using the CMV promoter in 18
the striatum of mice (Wang et al., 2003) resulted in efficient transduction of the 19
subventricular zone. In this study, GFP-positive cells were found in the olfactory bulb, the 20
region in which neural stem cells of the subventricular zone terminally differentiate (Alvarez-21
Buylla and Lim, 2004).22
In most animals, intrastriatal injections of rAAV2/1-rtTA-M2-WPRE-EGFP and rAAV2/1-23
CMV-EGFP resulted in efficient GFP expression in the subventricular zone (Fig. 6a,b). To 24
determine whether neural progenitors cells present in the subventricular zone (Alvarez-Buylla 25
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and Lim, 2004) could possibly be transduced, we examined the olfactory bulbs for GFP 1
expression. We detected numerous GFP-positive cells (5406.7±5049.9 per animal; n=3), 5 2
weeks after intrastriatal injection of rAAV2/1-CMV-EGFP ) (Fig. 6c) but not rAAV2/1-rtTA-3
M2-WPRE-EGFP (2.0±2.7 per animal; n=3) (data not shown).4
5
1.5. Immune response6
Markers for infiltrating lymphocytes (CD5) and microglial cells (CD11b) were absent or 7
restricted to the needle tract for both rAAV vectors, whereas a strong labeling for both 8
markers was observed after injection of an adenoviral vector expressing LacZ .  The ratio of 9
the mean optical densities of 3 sections on the injected side and intact sides was taken as a 10
measure of microglial cells activation (CD11b) or T cells infiltration (CD5) induced by vector 11
injection and transgene expression (data not shown). The optical density of sections labeled 12
for the astrocytic marker GFAP (known to be upregulated during inflammation) was also 13
similar for sham-injected animals and for both AAV vectors (data not shown).14
15
2. Midbrain Injections 16
2.1 Substantia nigra pars compacta17
Four 108 viral particles of rAAV2/1-rtTA-M2-WPRE-EGFP and rAAV2/1-CMV-EGFP were 18
infused into the right midbrain of adult rats dorsal to the substantia nigra.  To determine if the 19
WPRE sequence could possibly affect the biodistribution of transgene expression, 4 X 10820
viral particles of rAAV2/1-rtTA-M2- EGFP were injected at the same coordinates. 21
Whereas injections of  rAAV2/1-CMV-EGFP resulted in a wide GFP-positive area including 22
various structures i.e. SNpc, SNr, VTA and more dorsal structures (Figs 7a,b), the tetON 23
vector exclusively expressed GFP in the SNpc and VTA, regardless of the presence of the 24
WPRE sequence (rAAV2/1-rtTA-M2-WPRE-EGFP : see Figs.7c,d,e ;  rAAV2/1-rtTA-M2-25
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EGFP : data not shown). For the 3 vectors, the GFP-positive area covered the entirety of the 1
SNpc and VTA.2
To analyze the specificity and the efficiency of rAAV2/1 vectors for dopaminergic neurons of 3
the SNpc, colabeling for GFP and tyrosine hydroxylase (TH) was performed. Double-labeled 4
cells were identified by confocal microscopy. For each animal a total number of about 150 5
cells was counted in 3 sections at 250-µm intervals, taken around the injection site. 6
Specificity: Among the GFP-positive cells observed in the SNpc, a large proportion were TH-7
positive for the three vectors. Indeed, 54.05 ± 11.46% , 72.78 ± 17.39% and 76.75 ± 5.70% of 8
the GFP-positive cells were also TH-positive for rAAV2/1-CMV-EGFP, rAAV2/1-rtTA-M2-9
WPRE-EGFP and rAAV2/1-rtTA-M2- EGFP, respectively. The percentage of TH-positive 10
cells among GFP-positive cells was not different between the 3 vectors (one-way ANOVA).11
Efficiency: A large proportion the tyrosine hydroxylase-positive cells were expressing GFP. 12
Indeed, respectively 42.72 ± 20.57 % , 65.51 ± 18.05 % and 73.35± 7.80% of the tyrosine 13
hydorxylase-positive neurons of the SNpc were also GFP-positive when using the rAAV2/1-14
CMV-EGFP, rAAV2/1-rtTA-M2-WPRE-EGFP and rAAV2/1-rtTA-M2- EGFP vectors. The 15
percentage of GFP-positive cells among TH-positive cells was not different between the 3 16
vectors (one-way ANOVA).17
In order to address the mechanism of the observed differential biodistribution of GFP protein 18
with the CMV and tetON vectors, the gfp mRNA and DNA were quantified in the substantia 19
nigra and in the dorsal midbrain. Hirt low molecular weight DNA (hDNA) (Hirt, 1967) and 20
messenger RNAs (mRNA) were extracted from tissue punches and mRNAs were converted to 21
cDNA. Real-time quantitative PCR showed that the levels of gfp transcripts normalized 22
versus the levels of two different house keeping genes (YWHAZ and actin2) and relative to 23
the levels of hDNA were significantly higher (5-fold; p=0.0074) in the SN versus the 24
midbrain (Fig.8). A ~2.5-fold higher relative level of gfp transcripts in the SN versus the 25
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midbrain was also observed for the CMV vector (Fig.8). However, the difference was not 1
statistically significant (p=0.086).2
3
2.2 Striatum4
GFP-postive fibers were evidenced in the striatum (Fig.9) suggesting that GFP was 5
anterogradely transported from dopaminergic cell bodies of the SNpc to dopaminergic fibers 6
in the striatum. 7
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DISCUSSION1
2
Key factors for the success of neuroprotective gene therapy for Parkinson’s disease 3
are: a widespread  distribution of the neurotrophic factor in the putamen, the absence of 4
significant amounts of transgene product in connected regions which can induce adverse 5
effects as well as an optimal dose of the neurotrophic factor providing neuroprotection in the 6
absence of other, undesired biological effects. 7
We have previously shown that a single injection of the autoregulatory rAAV2/1-8
tetON vector drives doxycycline-dependent GDNF expression in a widespread area of the rat 9
striatum (Chtarto et al., 2007). We have extended these data and shown that the striatal 10
amount of GDNF could be modulated in function of the doxycycline dose. The GDNF 11
concentrations (~33 and 75 pg/mg tissue at doxycycline doses of 300 and 600 mg/l of 12
drinking water, respectively) were similar to that obtained by Eslamboli and coll. (Eslamboli 13
et al., 2005), i.e. 40 pg/mg tissue, providing neuroprotection and behavioural improvements in 14
the absence of effects on the dopamine metabolism.15
In the present study, we compared the biodistribution and cellular tropism of 16
rAAV2/1-tetON-EGFP and rAAV2/1-CMV-EGFP in the striatum and in the midbrain. 17
After striatal injection, although the vast majority of the GFP-positive cells were 18
neurons with both vectors, the percentage of GFP-positive astrocytes was significantly higher 19
when using the CMV vector. Furthermore, a different subset of neurons was expressing GFP 20
when using the tetON and the CMV vectors. Indeed, while rAAV2/1-CMV-EGFP expressed 21
the transgene in parvalbumin-positive interneurons and DARPP-32 projection neurons in 22
proportions roughly reflecting the presence of these two subpopulations of neurons (the vast 23
majority, i.e. 90–95%, of striatal neurons being DARPP-32-positive medium spiny projection 24
neurons) (Graveland and DiFiglia, 1985), rAAV2/1-tetON-EGFP targeted transgene 25
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expression in proportionally more parvalbumin-immunoreactive neurons (approx. 1 1
parvalbumin-positive for 2 DARPP-32-positive neurons). In addition, among DARPP-32 2
immunoreactive neurons, those projecting to the globus pallidus were expressing GFP 3
similarly with both vectors, whereas those projecting to the substantia nigra pars reticulata 4
were expressing GFP with the CMV but much less efficiently by the tetON vector as 5
evidenced by the GFP-positive projections observed in these structures. Retrograde transport 6
of viral particles from the striatum to the SNpc has been already reported with rAAV2/1 7
vectors using the CBA (Burger et al., 2004) and the CMV promoters (Wang et al., 2003). The 8
present study confirms retrograde transport when using the CMV promoter. However, it was 9
inefficient (approx. 100 cells per animal) as compared to the number of transduced cells 10
around the delivery site in the striatum (approx. 100,000 per animal). In contrast, only few 11
weakly labeled GFP-positive cells were detected in the SNpc of animals injected with 12
rAAV2/1-tetON in the striatum.  This could be due to a limited transgene inducibility in 13
dopaminergic neurons. However, after direct injection in the midbrain, very efficient GFP 14
expression in tyrosine hydroxylase-positive neurons was obtained with both vectors. 15
Altogether these data could suggest that high multiplicities of rAAV-tetON are required to 16
obtain an intracellular concentration of transactivator sufficient to induce the tetON system 17
and that the threshold number of viral genome copies could not be reached after retrograde 18
transport. Additional experiments, using for example labeled capsids, will be necessary to 19
address this question. In accordance with the very inefficient retrograde transport of AAV1 20
viral particles as well as anterograde transport of the transgene product, injection of AAV2/1 21
vectors expressing the human GDNF cDNA, resulted in low amounts of GDNF (not 22
significantly higher than the endogenous level) in the substantia nigra. 23
Another striking difference between the CMV and the tetON vectors consisted in the 24
differential transgene expression in the neural stem cells of the subventricular zone (SVZ). 25
Page 21 of 46 Human Gene Therapy
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
22
Indeed, although both vectors very efficiently expressed GFP in the SVZ, numerous GFP-1
positive cells were evidenced in the olfactory bulb (in which neural stem cells of the SVZ 2
migrate and differentiate (Alvarez-Buylla and Lim, 2004)) 5 weeks after injection of 3
rAAV2/1-CMV-EGFP but not rAAV2/1-tetON-EGFP. The absence of GFP-positive cells in 4
the olfactory bulb suggests that either the cells migrating to the olfactory bulb did not express 5
a detectable level of GFP due to low transcription efficiency or gene expression from the tet-6
responsive promoter was switched-off during migration and/or differentiation of neuroblasts. 7
The full characterization of initially-infected cells in the SVZ will require analysis shortly 8
after infection, before migration takes place. Regardless, the lack of GFP expression in the 9
migrating neuroblasts together with the efficient GFP expression in the neighbouring cells in 10
the SVZ, suggests that the rAAV2/1-tetON-EGFP could be used to express diffusible factors 11
acting in a paracrine way on neural stem cells while avoiding transgene expression in 12
olfactory bulb neurons. 13
Altogether, the data obtained after striatal injection support the potential use of 14
rAAV2/1-tetON for Parkinson’s disease GDNF gene therapy. Indeed, the inefficient 15
retrograde transport of  rAAV2/1 to the SNpc and anterograde transport of the transgene 16
product to the SNr, ensure a minimal amount of GDNF in the SN after striatal viral delivery. 17
Since the presence of high amounts of GDNF in the SN has been associated with aberrant 18
sprouting (Georgievska et al., 2002), the here described vector constitutes a safer alternative 19
for striatal GDNF gene delivery. In addition, the absence of transgene expression in the 20
olfactory bulb despite transduction of the subventricular zone when using the tetON but not 21
the CMV promoter-bearing rAAV2/1 vector, also renders the former safer than the latter.22
Another important finding of this study is that, after injection in the midbrain,23
rAAV2/1 vectors using the autoregulatory tetON transcription cassette provides preferential 24
transgenic expression in tyrosine hydroxylase-immunoreactive neurons of the substantia nigra 25
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pars compacta and ventral tegmental area. This property will be useful to evaluate the 1
function of genes potentially involved in the etiology of Parkinson’s disease as well as in the 2
physiology of dopaminergic neurons. Quantification of gfp transcripts relative to the amounts 3
of viral DNA evidenced a 5-fold higher expression level in the substantia nigra versus the 4
dorsal midbrain. Recombinant AAV2/2 vectors using constitutive promoters also efficiently 5
drive transgene expression into dopaminergic neurons when injected in the midbrain (Kirik et 6
al., 2002; Burger et al., 2004). Kirik and coll. (Kirik et al., 2002) using the CBA promoter 7
reported that the expression profile was not restrictive to dopaminergic neurons of the 8
substantia nigra pars compacta and ventral tegmental area but also affected the pars reticulata 9
of the substantia nigra and the mesensephalic reticular formation. 10
We can not exclude that the Woodchuck Hepatitis Virus Post-transcriptional 11
Regulatory Element (WPRE) could contribute to the observed transgene expression profile.12
Indeed, the WPRE sequence has been reported to contain enhancer activity (Kingsman et al., 13
2005). Furthermore, it has been shown to enhance the transgene expression efficiency from 14
rAAV2/2 vectors using different cellular (Paterna et al., 2000) and viral (Passini et al., 2003) 15
promoters. Whether the WPRE sequence modifies the cellular specificity of these vectors has 16
not been studied. In the present study, the WPRE sequence, placed downstream to the rtTA-17
M2 transactivator coding sequence did not significantly modify neither the efficiency nor the 18
profile of trangene expression from the autoregulatory AAV-tetON vector in the SNpc. These 19
data are in accordance with a previous study using the same vectors expressing the GDNF 20
cDNA (Chtarto et al., 2007), in which we have shown that the WPRE sequence did not 21
modify the GDNF tissue levels in the induced (+ doxycycline) state but resulted in a higher 22
basal level of GDNF expression (-doxycycline).  It could be that, the potentially increased 23
rtTAM2 expression in the rAAV2/1-rtTA-M2-WPRE relative to the rAAV2/1-rtTA-M2 24
vector, results in an increased expression of the transgene under the control of the 25
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tetracycline-responsive promoter in the non-induced but not in the induced state. In favour of 1
this hypothesis, the rtTA-M2 transactivator harbour a high affinity for doxycycline and a 2
higher stability in eukaryotic cells than the original rtTA, suggesting that it might saturate the 3
tetracycline operator sites in the induced state not allowing further improvements by 4
increasing its intracellular concentration.5
Overall, the restricted transgene expression of rAAV2/1-tetON as compared to 6
rAAV2/1-CMV could be due to i) lack of activation of the tetON system in cells which do not 7
accumulate enough transactivator in the absence of tetracycline; ii) absence of cellular factors 8
binding to the VP16 activation domain of the rtTA; iii) inefficient penetration or rapid 9
metabolisation of doxycycline in cells not expressing the transgene. However, some cell types 10
were expressing GFP as efficiently (TH-positive SNpc neurons) or more efficiently 11
(parvalbumin-immunoreactive striatal neurons) by the tetON than by the CMV vector.12
Differential transgene expression profiles of rAAV2/2-CMV and rAAV2/2-tTA 13
(tetOFF) has also been reported (Haberman et al., 2002). The authors showed that the same 14
transgene had opposite functional effects when expressed respectively under a CMV or 15
tetOFF transcriptional control and demonstrated using a gfp and a lacZ reporter gene 16
respectively, that the vectors were expressed mainly in different subpopulations of neurons.17
Immune reaction is a major issue in gene therapy. The rtTA-M2 transactivator is a 18
composite protein harbouring a viral as well as bacterial subdomains. Several studies report 19
immune responses directed against the rtTA after injection of tetracycline-regulatable viral 20
vectors in the muscle (Favre et al., 2002). However, in the brain of healthy animals, no 21
cellular immune reaction to the tTA/rtTA transactivator has been described using rAAV2/2 22
and adenoviral vectors (Fitzsimons et al., 2001; Xiong et al., 2008). These conclusions were 23
confirmed in the present study using rAAV2/1 pseudotyped vectors. In addition Xiong and 24
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coll. showed that systemic immunity against the rtTA-M2 transactivator did not lead to 1
inflammation or reduction of transgene expression in the striatum (Xiong et al., 2008).2
In conclusion, targeted transgene expression in specific brain cell populations might be 3
achieved by a combination of local injection and adequate choice of serotype and promoter. In 4
this respect, the here described rAAV2/1-tetON vector is an interesting tool i) to study the 5
function of genes in dopaminergic neurons of the SNpc; ii) to conditionally deliver diffusible 6
factors in the subventricular zone for the paracrine modification of neural stem cells. In 7
addition, regulatable transgene expression in the SNpc is of great interest for the study of the 8
function of Parkinson’s disease-related genes such as -synuclein, Parkin, etc…  in order to 9
characterize and distinguish permanent and reversible effects of the overexpression of the 10
wild-type and mutated forms of these genes.11
.12
13
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1LEGENDS TO FIGURES1
2
Figure 1. Dox-dependent concentration of GDNF in the striatum and the substantia nigra 3
after intrastriatal injection of rAAV2/1-rtTAM2-GDNF.4
Eight weeks after injection of rAAV2/1-rtTAM2-GDNF, brain extracts were analysed by 5
ELISA to detect GDNF concentration in the striatum (White boxes) and in the substantia 6
nigra (Black boxes). Striatal levels of GDNF at both Dox concentration in drinking water 7
(300mg/L and 600 mg/L) were highly significantly different from PBS control injection and 8
significantly and highly significantly different from the no Dox control condition for the 9
animals receiving 300mg of Dox per litre and 600 mg of Dox per litre respectively. GDNF 10
concentrations measured in the substantia nigra were not significantly different from the 11
endogenous level of PBS injected animals (one way ANOVA).12
13
Figure 2. Comparison of the transduction efficiency of rAAV2/1-CMV and rAAV2/1-tetON 14
vectors  in the striatum.15
Five weeks after injection of rAAV2/1 CMV (a) or tetON (b) vector into the striatum, 50 µm 16
vibratome brain sections were labeled with anti-gfp antibodies. GFP-immunopositive cells 17
were counted on every tenth section over a distance of 3mm (AP= +1.0 to AP=-2.0 from 18
bregma) [40] using an unbiased stereology method (40). Scale bar = 3mm.19
20
Figure 3. Cellular tropism of rAAV2/1-CMV and rAAV2/1-tetON vectors in the striatum.21
Panel a. Five weeks after injection of rAAV2/1 CMV (n= 4) or tetON vector (n=4) into the 22
striatum, brain sections were double-labeled with gfp (green fluorescence) and NeuN, GFAP, 23
parvalbumin or DARPP-32 (red fluorescence). Confocal pictures showing GFP and cell-24
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2specific markers double-labeled cells (yellow). Arrowheads indicate double-labeled cells. 1
Scale bar = 50 µm.2
Panel b. The proportions of colabeled cells were significantly different for the 2 vectors for 3
GFAP (5.9 ± 1.9 % of GFP-positive cells for the CMV vector versus 1.2 ± 2.2% for the tetON 4
vector; p < 0.05), parvalbumin (29.0±10.9% for the tetON versus 7.1±1.3% for the CMV 5
vector; p< 0.05) and DARPP-32 (91.6±2.3% for the CMV versus 66.7±5.1 % for the tetON 6
vector; p< 0.001); but not for the NeuN marker. (Student t test).  White boxes, CMV vector; 7
black boxes, tetON vector. Data are expressed as mean + SD.8
9
Figure 4. Differential anterograde transport of GFP in the SNr and globus pallidus after 10
injection of rAAV2/1-CMV and rAAV2/1-tetON vectors in the striatum.11
Five weeks after injection of rAAV2/1 CMV or tetON (a) vector into the right striatum, 12
midbrain sections were co-labeled with anti-GAD (red fluorescence) and anti-GFP (green 13
fluorescence) antibodies. Double-labeled fibers (yellow) were evidenced in the right SNr. 14
Alternatively, sections were labeled by anti-GFP antibodies using a sensitive biotin-15
streptavidin/peroxidase/DAB staining method (b). Scale bar = 1mm (a) and 0.5 mm (b).16
Panel c. Five weeks after injection of rAAV2/1 CMV or tetON vector in the striatum, 17
sections at the level of the globus pallidus or substantia nigra were labeled with anti-GFP 18
antibody. The optical density of the fibers (panels d,e for substantia nigra and f,g for globus 19
pallidus) was measured on greyscale pictures with the software Image J on at least 5 different 20
sites per section into the transduction area and in the contralateral structure. Measures were 21
made on 1 or 2 sections per animal (n=4) for the globus pallidus and on 2 or 3 sections per 22
animal (n=4) for the substantia nigra pars reticulata. The fiber labeling for CMV and tetON 23
vectors was significantly different in the substantia nigra (p=0.0119) but not in the globus 24
pallidus (p>0.05). Data are expressed in mean ± SD.25
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Figure  5. Retrograde transport in the substantia nigra pars compacta.2
Five weeks after injection of rAAV2/1 CMV-EGFP into the right striatum, midbrain sections 3
were co-labeled with anti-TH (red fluorescence) and anti-GFP (green fluorescence) 4
antibodies. Double labeled cell bodies (yellow) were evidenced in the right SNpc. Arrowhead 5
indicates a double-labeled cell.  Scale bar = 50 µm.6
7
Figure 6. Differential transgene expression from rAAV2/1-CMV and rAAV2/1-tetON vectors 8
in the olfactory bulb.9
Five weeks after injection of rAAV2/1 CMV or tetON vector into the striatum, sections at the 10
level of the striatum (a, b) or olfactory bulb (c) were labeled with anti-GFP antibodies. GFP-11
positive cells were evidenced in the subventricular zone with both the CMV (a) and the tetON 12
(b) vectors. Sections at the level of the olfactory bulb showed GFP-positive cells in animals 13
injected with the CMV vector (c) but not the tetON vector (data not shown). Scale bar = 125 14
µm.15
16
Figure 7. Specificity of rAAV2/1-tetON vector for dopaminergic neurons of the substantia 17
nigra pars compacta and ventral tegmental area.18
Five weeks after injection of rAAV2/1 CMV (a, b) or tetON (c, d, e) vector into the midbrain, 19
sections were labeled with anti-GFP (green fluorescence) and anti-TH (red fluorescence) 20
antibodies. The proportion of TH-positive cells that were also GFP-positive (yellow 21
fluorescence) was not significantly different for the 2 vectors (Student t test). Arrowheads 22
indicate double-labeled cells. Panels a, c, d, fluorescence microscopy; b, e, confocal 23
microscopy. Scale bar = 500 µm (a, c), 125 µm (d) and 50 µm (b, e).24
25
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4Figure 8. Normalized gfp expression levels measured by qPCR in the dorsal midbrain and 1
substantia nigra after injection of rAAVA2/1-CMV or rAAV2/1-tetON vectors in the midbrain.2
Five weeks after injection of rAAV2/1-CMV-EGFP or rAAV2/1-rtTAM2-EGFP, mRNA and 3
low molecular weight DNA were extracted from substantia nigra or dorsal midbrain tissue. 4
mRNAs were reverse transcribed to cDNA. Gfp sequences were quantified by qPCR. mRNA 5
levels were normalised for house keeping genes and then relative to hDNA levels. The level 6
of gfp transcripts expressed by the tetON vector was 5-fold higher in the SN than in the dorsal 7
midbrain (p=0.0074), whereas the level of gfp transcripts expressed by the CMV vector was 8
not significantly different in the SN and in the dorsal midbrain (p=0.08624). Data are 9
expressed in gfp relative expression units, defined as the gfp expression level of the less 10
expressed sample in the experiment after normalisation for house keeping genes and amounts 11
of hDNA (gfp copies/mg tissue). White boxes, midbrain; black boxes, substantia nigra. Data 12
are expressed in mean + S. E. M. (n=7).13
14
Figure 9. Anterograde transport of GFP in the striatum after injection of rAAV2/1-CMV and 15
rAAV2/1-tetON vectors  in the midbrain.16
Five weeks after injection of rAAV2/1 CMV or tetON vectors into the right midbrain, 17
striatum sections were labeled with anti-GFP (green fluorescence) antibodies. GFP-positive 18
fibers were evidenced in the right striatum. Scale bar = 50µm.19
20
21
22
23
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Figure 1. Dox-dependent concentration of GDNF in the striatum and the substantia nigra 
after intrastriatal injection of rAAV2/1-rtTAM2-GDNF. Eight weeks after injection of 
rAAV2/1-rtTAM2-GDNF, brain extracts were analysed by ELISA to detect GDNF 
concentration in the striatum (White boxes) and in the substantia nigra (Black boxes). 
Striatal levels of GDNF at both Dox concentration in drinking water (300mg/L and 600 
mg/L) were highly significantly different from PBS control injection and significantly and 
highly significantly different from the no Dox control condition for the animals receiving 
300mg of Dox per litre and 600 mg of Dox per litre respectively. GDNF concentrations 
measured in the substantia nigra were not significantly different from the endogenous 
level of PBS injected animals (one way ANOVA).  
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Figure 2. Comparison of the transduction efficiency of rAAV2/1-CMV and rAAV2/1-tetON 
vectors in the striatum. Five weeks after injection of rAAV2/1 CMV (a) or tetON (b) vector 
into the striatum, 50 µm vibratome brain sections were labeled with anti-gfp antibodies. 
GFP-immunopositive cells were counted on every tenth section over a distance of 3mm 
(AP= +1.0 to AP=-2.0 from bregma) [40] using an unbiased stereology method (40). 
Scale bar = 3mm.  
45x23mm (600 x 600 DPI)  
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Figure 3. Cellular tropism of rAAV2/1-CMV and rAAV2/1-tetON vectors in the striatum. 
Panel a. Five weeks after injection of rAAV2/1 CMV (n= 4) or tetON vector (n=4) into the 
striatum, brain sections were double-labeled with gfp (green fluorescence) and NeuN, 
GFAP, parvalbumin or DARPP-32 (red fluorescence). Confocal pictures showing GFP and 
cell-specific markers double-labeled cells (yellow). Arrowheads indicate double-labeled 
cells. Scale bar = 50 m. Panel b. The proportions of colabeled cells were significantly 
different for the 2 vectors for GFAP (5.9 ± 1.9 % of GFP-positive cells for the CMV vector 
versus 1.2 ± 2.2% for the tetON vector; p < 0.05), parvalbumin (29.0±10.9% for the 
tetON versus 7.1±1.3% for the CMV vector; p< 0.05) and DARPP-32 (91.6±2.3% for the 
CMV versus 66.7±5.1 % for the tetON vector; p< 0.001); but not for the NeuN marker. 
(Student t test). White boxes, CMV vector; black boxes, tetON vector. Data are expressed 
as mean + SD.  
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Figure 4. Differential anterograde transport of GFP in the SNr and globus pallidus after 
injection of rAAV2/1-CMV and rAAV2/1-tetON vectors in the striatum. Five weeks after 
injection of rAAV2/1 CMV or tetON (a) vector into the right striatum, midbrain sections 
were co-labeled with anti-GAD (red fluorescence) and anti-GFP (green fluorescence) 
antibodies. Double-labeled fibers (yellow) were evidenced in the right SNr. Alternatively, 
sections were labeled by anti-GFP antibodies using a sensitive biotin-
streptavidin/peroxidase/DAB staining method (b). Scale bar = 1mm (a) and 0.5 mm (b). 
Panel c. Five weeks after injection of rAAV2/1 CMV or tetON vector in the striatum, 
sections at the level of the globus pallidus or substantia nigra were labeled with anti-GFP 
antibody. The optical density of the fibers (panels d,e for substantia nigra and f,g for 
globus pallidus) was measured on greyscale pictures with the software Image J on at 
least 5 different sites per section into the transduction area and in the contralateral 
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structure. Measures were made on 1 or 2 sections per animal (n=4) for the globus 
pallidus and on 2 or 3 sections per animal (n=4) for the substantia nigra pars reticulata. 
The fiber labeling for CMV and tetON vectors was significantly different in the substantia 
nigra (p=0.0119) but not in the globus pallidus (p>0.05). Data are expressed in mean ± 
SD.  
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Figure 5. Retrograde transport in the substantia nigra pars compacta. Five weeks after 
injection of rAAV2/1 CMV-EGFP into the right striatum, midbrain sections were co-labeled 
with anti-TH (red fluorescence) and anti-GFP (green fluorescence) antibodies. Double 
labeled cell bodies (yellow) were evidenced in the right SNpc. Arrowhead indicates a 
double-labeled cell. Scale bar = 50 m. 
33x12mm (600 x 600 DPI)  
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Figure 6. Differential transgene expression from rAAV2/1-CMV and rAAV2/1-tetON 
vectors in the olfactory bulb. Five weeks after injection of rAAV2/1 CMV or tetON vector 
into the striatum, sections at the level of the striatum (a, b) or olfactory bulb (c) were 
labeled with anti-GFP antibodies. GFP-positive cells were evidenced in the subventricular 
zone with both the CMV (a) and the tetON (b) vectors. Sections at the level of the 
olfactory bulb showed GFP-positive cells in animals injected with the CMV vector (c) but 
not the tetON vector (data not shown). Scale bar = 125 Figure 6. Differential transgene 
expression from rAAV2/1-CMV and rAAV2/1-tetON vectors in the olfactory bulb. Five 
weeks after injection of rAAV2/1 CMV or tetON vector into the striatum, sections at the 
level of the striatum (a, b) or olfactory bulb (c) were labeled with anti-GFP antibodies. 
GFP-positive cells were evidenced in the subventricular zone with both the CMV (a) and 
the tetON (b) vectors. Sections at the level of the olfactory bulb showed GFP-positive 
cells in animals injected with the CMV vector (c) but not the tetON vector (data not 
shown). Scale bar = 125 m. 
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Figure 7. Specificity of rAAV2/1-tetON vector for dopaminergic neurons of the substantia 
nigra pars compacta and ventral tegmental area. Five weeks after injection of rAAV2/1 
CMV (a, b) or tetON (c, d, e) vector into the midbrain, sections were labeled with anti-GFP 
(green fluorescence) and anti-TH (red fluorescence) antibodies. The proportion of TH-
positive cells that were also GFP-positive (yellow fluorescence) was not significantly 
different for the 2 vectors (Student t test). Arrowheads indicate double-labeled cells. 
Panels a, c, d, fluorescence microscopy; b, e, confocal microscopy. Scale bar = 500 m
(a, c), 125 m (d) and 50 m (b, e). 
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Figure 8. Normalized gfp expression levels measured by qPCR in the dorsal midbrain and 
substantia nigra after injection of rAAVA2/1-CMV or rAAV2/1-tetON vectors in the 
midbrain. Five weeks after injection of rAAV2/1-CMV-EGFP or rAAV2/1-rtTAM2-EGFP, 
mRNA and low molecular weight DNA were extracted from substantia nigra or dorsal 
midbrain tissue. mRNAs were reverse transcribed to cDNA. Gfp sequences were 
quantified by qPCR. mRNA levels were normalised for house keeping genes and then 
relative to hDNA levels. The level of gfp transcripts expressed by the tetON vector was 5-
fold higher in the SN than in the dorsal midbrain (p=0.0074), whereas the level of gfp 
transcripts expressed by the CMV vector was not significantly different in the SN and in 
the dorsal midbrain (p=0.08624). Data are expressed in gfp relative expression units, 
defined as the gfp expression level of the less expressed sample in the experiment after 
normalisation for house keeping genes and amounts of hDNA (gfp copies/mg tissue). 
White boxes, midbrain; black boxes, substantia nigra. Data are expressed in mean + S. E. 
M. (n=7).  
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Figure 9. Anterograde transport of GFP in the striatum after injection of rAAV2/1-CMV 
and rAAV2/1-tetON vectors in the midbrain. Five weeks after injection of rAAV2/1 CMV or 
tetON vectors into the right midbrain, striatum sections were labeled with anti-GFP 
(green fluorescence) antibodies. GFP-positive fibers were evidenced in the right striatum. 
Scale bar = 50 Im.  
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